Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Replimune Group, Inc.

REPL · Nasdaq · CIK 0001737953 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

13 Form 4 transaction lines observed in the same window
12 sales · 1 option, withholding, award, gift or other lines

Last qualifying purchaseNo qualifying purchase is present in the local Form 4 history.

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Hill Emily LuisaChief Financial Officer
▼▼▼
Sarchi ChristopherChief Commercial Officer
▼▼
Xynos KonstantinosChief Medical Officer
▼▼
Schwendenman AndrewChief Accounting Officer
▼▼
Patel SushilChief Executive Officer
▼▼
Astley-Sparke PhilipDirector
▼○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot.—

Recent Form 4 activity

0Purchases
17Sales
14Other Form 4 lines
30SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING12 sale line(s) · context only
OTHER1 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
23,128,025
Previous report
22,754,597
Avg daily volume
2,136,193
Days to cover
10.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

No qualifying code P equity purchase is present in the local Form 4 history.

Form 4 evidence

31 transaction lines in the latest 365-day window; 334 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-20Astley-Sparke PhilipGift (G)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-08-17Hill Emily LuisaSale (S)Common Stock9,256USD 14.28USD 132,176SEC filing ↗
2026-08-10Xynos KonstantinosSale (S)Common Stock11,447USD 12.97USD 148,468SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-20Astley-Sparke PhilipGift (G)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-08-17Hill Emily LuisaSale (S)Common Stock9,256USD 14.28USD 132,176SEC filing ↗
2026-08-10Xynos KonstantinosSale (S)Common Stock11,447USD 12.97USD 148,468SEC filing ↗
2026-08-10Schwendenman AndrewSale (S)Common Stock7,632USD 12.97USD 98,987SEC filing ↗
2026-08-10Patel SushilSale (S)Common Stock39,341USD 12.97USD 510,253SEC filing ↗
2026-08-10Hill Emily LuisaSale (S)Common Stock11,448USD 12.97USD 148,481SEC filing ↗
2026-06-01Sarchi ChristopherSale (S)Common Stock12,000USD 9.24USD 110,880SEC filing ↗
2026-05-18Xynos KonstantinosSale (S)Common Stock14,023USD 5.08USD 71,237SEC filing ↗
2026-05-18Schwendenman AndrewSale (S)Common Stock7,894USD 5.08USD 40,102SEC filing ↗
2026-05-18Sarchi ChristopherSale (S)Common Stock8,626USD 5.08USD 43,820SEC filing ↗
2026-05-18Patel SushilSale (S)Common Stock37,324USD 5.08USD 189,606SEC filing ↗
2026-05-18Hill Emily LuisaSale (S)Common Stock7,812USD 5.08USD 39,685SEC filing ↗
2026-05-18Astley-Sparke PhilipSale (S)Common Stock17,657USD 5.08USD 89,698SEC filing ↗
2026-04-02Sarchi ChristopherSale (S)Common Stock6,500USD 8.01USD 52,065SEC filing ↗
2026-04-01Xynos KonstantinosAward / grant (A)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-04-01Schwendenman AndrewAward / grant (A)Common Stock36,667USD 0.00USD 0SEC filing ↗
2026-04-01Sarchi ChristopherAward / grant (A)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-04-01Patel SushilAward / grant (A)Common Stock251,240USD 0.00USD 0SEC filing ↗
2026-04-01Hill Emily LuisaAward / grant (A)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-04-01Astley-Sparke PhilipAward / grant (A)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-02-18Astley-Sparke PhilipGift (G)Common Stock25,000USD 0.00USD 0SEC filing ↗
2025-12-19Xynos KonstantinosAward / grant (A)Common Stock60,000USD 0.00USD 0SEC filing ↗
2025-12-19Schwendenman AndrewAward / grant (A)Common Stock10,000USD 0.00USD 0SEC filing ↗
2025-12-19Sarchi ChristopherAward / grant (A)Common Stock35,000USD 0.00USD 0SEC filing ↗
2025-12-19Patel SushilAward / grant (A)Common Stock200,000USD 0.00USD 0SEC filing ↗
2025-12-19Hill Emily LuisaAward / grant (A)Common Stock60,000USD 0.00USD 0SEC filing ↗
2025-12-09Dhingra KapilSale (S)Common Stock3,169USD 10.40USD 32,958SEC filing ↗
2025-12-09Dhingra KapilOption exercise / conversion (M)Common Stock3,169USD 1.75USD 5,546SEC filing ↗
2025-12-02Patel SushilSale (S)Common Stock10,000USD 11.13USD 111,300SEC filing ↗
2025-11-17Xynos KonstantinosSale (S)Common Stock7,248USD 9.10USD 65,957SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerREPL
CIK0001737953
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history334 transaction lines from 2020-02-12 to 2026-08-20
0 P purchase lines · 252 S sale lines · 82 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.